1-6 of 6
Chris Tse
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling

Open Access
Wei Li, Renata Sano, Mutiah Apatira, Felix DeAnda, Tarikere Gururaja, Muhua Yang, Greta Lundgaard, Chin Pan, Jing Liu, Yongjiao Zhai, Woo Hyun Yoon, Longcheng Wang, Chris Tse, Andrew J. Souers, Chih-Hung Lee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (1): 35–46.
https://doi.org/10.1158/1535-7163.MCT-22-0642
Published: 03 January 2024
View article titled, Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling
Open the PDF for Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling in another window
Includes: Supplementary data
Journal Articles

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

Free
Julie L. Wilsbacher, Min Cheng, Dong Cheng, Samuel A.J. Trammell, Yan Shi, Jun Guo, Stormy L. Koeniger, Peter J. Kovar, Yupeng He, Sujatha Selvaraju, H. Robin Heyman, Bryan K. Sorensen, Richard F. Clark, T. Matthew Hansen, Kenton L. Longenecker, Diana Raich, Alla V. Korepanova, Steven Cepa, Danli L. Towne, Vivek C. Abraham, Hua Tang, Paul L. Richardson, Shaun M. McLoughlin, Ilaria Badagnani, Michael L. Curtin, Michael R. Michaelides, David Maag, F. Gregory Buchanan, Gary G. Chiang, Wenqing Gao, Saul H. Rosenberg, Charles Brenner, Chris Tse
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (7): 1236–1245.
https://doi.org/10.1158/1535-7163.MCT-16-0819
Published: 04 July 2017
View article titled, Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors
Open the PDF for Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors in another window
Includes: Supplementary data
Journal Articles

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

Free
Jun Chen, Sha Jin, Vivek Abraham, Xiaoli Huang, Bernard Liu, Michael J. Mitten, Paul Nimmer, Xiaoyu Lin, Morey Smith, Yu Shen, Alexander R. Shoemaker, Stephen K. Tahir, Haichao Zhang, Scott L. Ackler, Saul H. Rosenberg, Heather Maecker, Deepak Sampath, Joel D. Leverson, Chris Tse, Steven W. Elmore
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (12): 2340–2349.
https://doi.org/10.1158/1535-7163.MCT-11-0415
Published: 07 December 2011
View article titled, The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
Open the PDF for The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo in another window
Includes: Supplementary data
Journal Articles

Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.

Free
Michael L. Curtin, Robin Heyman, Robin R. Frey, Niru B. Soni, Patick A. Marcotte, Lori J. Pease, Keith B. Glaser, Terrance J. Magoc, Paul Tapang, Daniel H. Albert, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Zhiwen Guan, Ruth L. Martin, Kent D. Stewart, Chris Tse, Steven K. Davidsen, Michael R. Michaelides
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C202.
https://doi.org/10.1158/1535-7163.TARG-11-C202
Published: 12 November 2011
View article titled, Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.
Journal Articles

Abstract B231: Potent in vivo activity of the Aurora kinase inhibitor ABT-348 in a broad spectrum of histological types: Evaluation of efficacy, dosing/scheduling, and PK/PD.

Free
Cherrie K. Donawho, Debra Montgomery, Luis E. Rodriguez, Yi-Chun Wang, Paul E. Ellis, Lance Kaleta, Gail Bukofzer, Jennifer Bouska, Jerry Clarin, Sally Schlessinger, Baole Wang, Keith Glaser, Mike Michaelides, Daniel Albert, Chris Tse, David J. Frost, Joann P. Palma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B231.
https://doi.org/10.1158/1535-7163.TARG-11-B231
Published: 12 November 2011
View article titled, Abstract B231: Potent in vivo activity of the Aurora kinase inhibitor ABT-348 in a broad spectrum of histological types: Evaluation of efficacy, dosing/scheduling, and PK/PD.
Journal Articles

Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.

Free
Keith B. Glaser, Junling Li, Patrick A. Marcotte, Terrance J. Magoc, Jun Guo, David R. Reuter, Paul Tapang, Ru-Qi Wei, Lori J. Pease, Mai H. Bui, Zehan Chen, Robin R. Frey, Eric F. Johnson, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Michael L. Curtin, Cherrie K. Donawho, Michael R. Michaelides, Chris Tse, Steven K. Davidsen, Daniel H. Albert
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A239.
https://doi.org/10.1158/1535-7163.TARG-11-A239
Published: 12 November 2011
View article titled, Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.